Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Il-Yang Pharm. Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01511289
First received: January 3, 2012
Last updated: March 5, 2015
Last verified: March 2015
  Purpose

In this study, the efficacy and safety of two radotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).


Condition Intervention Phase
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Bone Marrow Diseases
Hematologic Diseases
Drug: Imatinib
Drug: Radotinib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase

Resource links provided by NLM:


Further study details as provided by Il-Yang Pharm. Co., Ltd.:

Primary Outcome Measures:
  • Rate of Major Molecular Response(MMR) by 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    Rate of Major Molecular Response (MMR) at Any Time within 12 months. MMR by 12 months will be assessed as responder if the patient has response at any time within 12 months.

    A major molecular response rate is defined as the ratio (%) of BCR-ABL/ABL ≤ 0.1% by international scale or a 3-log reduction in BCR-ABL transcript level from standardized baseline, as measured by standardized RQ-PCR assay.



Secondary Outcome Measures:
  • Rate of complete cytogenetic response (CCyR) by 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Complete cytogenetic response is defined as complete disappearance of Philadelphia-positive in at least 20 metaphases examined. Chromosome analysis performed on less than 20 metaphases will not be accepted for this study

  • Rate of complete molecular response (CMR) by 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]

    Complete molecular response is defined as negative BCR-ABL transcript levels, as measured twice by the internationally standardized RQ-PCR assay.

    The rate of complete molecular response by cycle 12 is defined as an at least 4.5 log reduction in BCR-ABL transcript levels from standardized baseline or BCR-ABL/ABL % ≤ 0.005% by the international scale.


  • Rate of major molecular response (MMR) at 12 months [ Time Frame: 12 month ] [ Designated as safety issue: No ]

    Rate of Major Molecular response will be assessed at 12 months at that timepoint.

    Number of Participants With Major Molecular Response (MMR) at 12 months.


  • Rate of subjects with disease progression [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Disease progression by month 12 will be compared between each groups.


Enrollment: 242
Study Start Date: August 2011
Estimated Study Completion Date: February 2018
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Imatinib
Imatinib 400mg QD
Drug: Imatinib
400mg/Tab, QD
Other Names:
  • Glivec
  • Gleevec
Experimental: Radotinib 600mg
Radotinib 300mg BID
Drug: Radotinib
100mg or 200mg/Capsule, 300mg or 400mg BID
Other Name: IY5511HCl
Experimental: Radotinib 800mg
Radotinib 400mg BID
Drug: Radotinib
100mg or 200mg/Capsule, 300mg or 400mg BID
Other Name: IY5511HCl

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with confirmed diagnosis of chronic phase CML within last 3 months
  • Patients with cytogenetically confirmed Ph positive CML in early chronic phase

Exclusion Criteria:

  • Patients with Philadelphia chromosome negative but BCR-ABL positive CML
  • Patients who used imatinib for 8 days or longer before study entry
  • Patients who had been treated with other targeted anti-cancer therapy, except for Hydrea or Agrylin, which inhibits the growth of leukemic cells
  • Patients with impaired cardiac function
  • Cytologically confirmed CNS involvement
  • Severe or uncontrolled chronic medical condition
  • Other significant congenital or acquired bleeding disorders that are not related to underlying leukemia
  • Patients who had a major surgery within 4 weeks prior to study entry or has not recovered from side effects of such surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01511289

Locations
Indonesia
Local Institution
Jakarta, Indonesia
Korea, Republic of
Local Institution
Busan, Korea, Republic of, 602-715
Local Institution
Busan, Korea, Republic of, 602-739
Local Institution
Busan, Korea, Republic of, 633-165
Local Institution
Daegu, Korea, Republic of, 700-712
Local Institution
Daejeon, Korea, Republic of, 301-721
Local Institution
Gyeonggi-do, Korea, Republic of, 442-723
Local Institution
Gyeonggi-do, Korea, Republic of, 443-721
Local Institution
Gyeonggi-do, Korea, Republic of, 431-070
Local Institution
Incheon, Korea, Republic of, 405-760
Local Institution
Jeollabuk-do, Korea, Republic of, 561-712
Local Institution
Jeonnam, Korea, Republic of, 519-763
Local Institution
Seoul, Korea, Republic of, 158-710
Local Institution
Seoul, Korea, Republic of, 110-746
Local Institution
Seoul, Korea, Republic of, 138-736
Local Institution
Seoul, Korea, Republic of, 152-703
Local Institution
Seoul, Korea, Republic of, 137-701
Local Institution
Ulsan, Korea, Republic of, 682-714
Local Institution
Wonju, Korea, Republic of, 220-701
Philippines
Local Institution
Batangas, Philippines
Local Institution
Manilla, Philippines
Thailand
Local Institution
Bangkok, Thailand
Sponsors and Collaborators
Il-Yang Pharm. Co., Ltd.
Investigators
Study Director: IL-YANG PHARM IL-YANG Pharmaceutical. Co., LTD
  More Information

No publications provided

Responsible Party: Il-Yang Pharm. Co., Ltd.
ClinicalTrials.gov Identifier: NCT01511289     History of Changes
Other Study ID Numbers: IY5511A3001
Study First Received: January 3, 2012
Last Updated: March 5, 2015
Health Authority: South Korea: Ministry of Food and Drug Safety (MFDS)
Indonesia: National Agency of Drug and Food Control
Philippines: Bureau of Food and Drugs
Thailand: Ethical Committee

Keywords provided by Il-Yang Pharm. Co., Ltd.:
Radotinib
CML-CP
Chronic Myeloid Leukemia, chronic phase

Additional relevant MeSH terms:
Bone Marrow Diseases
Hematologic Diseases
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Philadelphia Chromosome
Chromosome Aberrations
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Translocation, Genetic
Imatinib
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on August 30, 2015